Revance Therapeutics Inc.‘s $17 million agreement with investors earned a federal judge’s initial blessing to resolve allegations the anti-wrinkle injection developer hid it might be in breach of a dermal-filler contract, lowering its buyout price.
The settlement class preliminarily approved by Judge Eli Richardson April 10 covers those who acquired Revance securities from Feb. 29, 2024, through the close of the biotechnology company’s acquisition by Crown Laboratories Inc. on Feb. 6, 2025. If given final approval by the US District Court for the Middle District of Tennessee, the deal would end a proposed class action tied to disclosures about ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.